82 related articles for article (PubMed ID: 18349438)
1. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs.
Duintjer Tebbens RJ; Thompson KM; Hunink MG; Mazzuchi TA; Lewandowski D; Kurowicka D; Cooke RM
Med Decis Making; 2008; 28(2):182-200. PubMed ID: 18349438
[TBL] [Abstract][Full Text] [Related]
2. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
Brisson M; Edmunds WJ
Med Decis Making; 2006; 26(5):434-46. PubMed ID: 16997923
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive.
Mogasale V; Barendregt J
Aust N Z J Public Health; 2011 Apr; 35(2):180-6. PubMed ID: 21463417
[TBL] [Abstract][Full Text] [Related]
4. Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam.
Kim SY; Goldie SJ; Salomon JA
Med Decis Making; 2010; 30(5):E1-E28. PubMed ID: 20729510
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis.
Broughton EI
J Public Health (Oxf); 2007 Dec; 29(4):441-8. PubMed ID: 17875589
[TBL] [Abstract][Full Text] [Related]
6. The costs of future polio risk management policies.
Tebbens RJ; Sangrujee N; Thompson KM
Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
[TBL] [Abstract][Full Text] [Related]
7. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
Ho AM; Nelson EA; Walker DG
Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
[TBL] [Abstract][Full Text] [Related]
8. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models.
Mauskopf J; Talbird S; Standaert B
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):357-71. PubMed ID: 22812559
[TBL] [Abstract][Full Text] [Related]
9. Handling input correlations in pharmacoeconomic models.
Naveršnik K; Rojnik K
Value Health; 2012 May; 15(3):540-9. PubMed ID: 22583465
[TBL] [Abstract][Full Text] [Related]
10. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
Dasbach EJ; Elbasha EH; Insinga RP
Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
[TBL] [Abstract][Full Text] [Related]
11. Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly.
Whang W; Sisk JE; Heitjan DF; Moskowitz AJ
Int J Technol Assess Health Care; 1999; 15(3):563-72. PubMed ID: 10874382
[TBL] [Abstract][Full Text] [Related]
12. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
Jeuland M; Whittington D
Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
[TBL] [Abstract][Full Text] [Related]
13. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria.
Maire N; Shillcutt SD; Walker DG; Tediosi F; Smith TA
Value Health; 2011 Dec; 14(8):1028-38. PubMed ID: 22152171
[TBL] [Abstract][Full Text] [Related]
16. Measuring uncertainty importance: investigation and comparison of alternative approaches.
Borgonovo E
Risk Anal; 2006 Oct; 26(5):1349-61. PubMed ID: 17054536
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity analysis of a two-dimensional probabilistic risk assessment model using analysis of variance.
Mokhtari A; Frey HC
Risk Anal; 2005 Dec; 25(6):1511-29. PubMed ID: 16506979
[TBL] [Abstract][Full Text] [Related]
18. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.
O'Hagan A; Stevenson M; Madan J
Health Econ; 2007 Oct; 16(10):1009-23. PubMed ID: 17173339
[TBL] [Abstract][Full Text] [Related]
19. A probabilistic arsenic exposure assessment for children who contact chromated copper arsenate (CCA)-treated playsets and decks, Part 2: Sensitivity and uncertainty analyses.
Xue J; Zartarian VG; Ozkaynak H; Dang W; Glen G; Smith L; Stallings C
Risk Anal; 2006 Apr; 26(2):533-41. PubMed ID: 16573638
[TBL] [Abstract][Full Text] [Related]
20. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community.
Poulos C; Bahl R; Whittington D; Bhan MK; Clemens JD; Acosta CJ
J Health Popul Nutr; 2004 Sep; 22(3):311-21. PubMed ID: 15609784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
